Virax Biolabs warrants exercised at $6 for $3.3 million proceeds
Share
Listen to the news
Virax Biolabs warrants exercised at $6 for $3.3 million proceeds
  • Virax Biolabs entered an agreement for immediate cash exercise of 548,000 preferred investment options at a reduced $6 per share.
  • Gross proceeds expected at about $3.3 million; closing targeted for July 10, 2026.
  • Company to issue unregistered Series A preferred investment options for 548,000 shares, contingent on shareholder approval of an authorized share increase.
  • Also to issue unregistered short-term Series B preferred investment options for 1,096,000 shares; both new warrants carry a $6 exercise price.
  • Virax plans to file an SEC registration statement for resale of shares issuable on exercise of the new warrants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607091335PR_NEWS_USPR_____DA01607) on July 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending